Cardiac Involvement in Rheumatoid Arthritis

Handbook of Systemic Autoimmune Diseases

Volumn 1, Issue , 2003, Pages 121-143

  Goodson, Nicola J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649646238     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(03)01009-2     Document Type: Review

References (205)

1. Ahern M., Lever J.V., and Cosh J. Complete heart block in rheumatoid arthritis. Ann. Rheum. Dis. 42 4 (1983) 389-397
2. Albada-Kuipers G.A., Bruijn J.A., Westedt M.L., et al. Coronary arteritis complicating rheumatoid arthritis. Ann. Rheum. Dis. 45 11 (1986) 963-965
3. Albert M.A., Danielson E., Rifai N., et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 1 (2001) 64-70
4. Alldred A., and Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. 2 1 (2001) 125-137
5. Allebeck P., Ahlbom A., and Allander E. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate. Eleven-year follow-up of an epidemiological study. Scand. J. Rheumatol. 10 4 (1981) 301-306
6. Aman S., Paimela L., Leirisalo-Repo M., et al. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study. Rheumatology 39 9 (2000) 1009-1013
7. Anker S.D., and Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86 2-3 (2002) 123-130
8. Asanuma Y., and Mizushima Y. Serum lipoprotein (a) and apolipoprotein (a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum. 42 (1999) 443-447
9. Austin M.A. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr. Atheroscler. Rep. 2 3 (2000) 200-207
10. Bacon P.A., and Gibson D.G. Cardiac involvement in rheumatoid arthritis. An echocardiographic study. Ann. Rheum. Dis. 33 1 (1974) 20-24
11. Bacon P.A., Raza K., Banks M., et al. The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int. Rev. Immunol. 21 1 (2002) 1-17
12. Baigent C., and Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 48 1 (2003) 12-20 Review article appraising the effects of different NSAIDs on the cardiovascular system
13. Banks M., Flint J., Bacon P.A., et al. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease. Arthritis Rheum. 43 9 (2000) 1909 Study using myocardial perfusion scanning and clinical assessments of IHD in a group of RA patients revealed a high prevalence of IHD but much was clinically silent
14. Bas S., Genevay S., and Mensi N. False positive elevation of cardiac troponin I in seropositive rheumatoid arthritis. J. Rheumatol. 29 12 (2002) 2665
15. Bely M., Apathy A., and Beke-Martos E. Cardiac changes in rheumatoid arthritis. Acta Morphol. Hung. 40 1-4 (1992) 149-186
16. Bergholm R., Leirisalo-Repo M., Vehkavaara S., et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler. Thromb. Vasc. Biol. 22 10 (2002) 1637-1641
17. Berkanovic E., and Hurwicz M. Rheumatoid arthritis and comorbidity. J. Rheumatol. 17 (1990) 888-892
18. Berliner J. Introduction. Lipid oxidation products and atherosclerosis. Vasc. Pharmacol. 38 4 (2002) 187-191
19. Bjornadal L., Baecklund E., Yin, et al. Decreasing mortality in patients with rheumatoid arthritis: Results from a large population based cohort in Sweden, 1964-95. J. Rheumatol. 29 5 (2002) 906-912
20. Blake G.J., and Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ. Res. 89 9 (2001) 763-771
21. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J. Int. Med. 252 4 (2002) 283-294 Recent review of emerging inflammatory CVD risk factors and their mechanisms
22. Boersma E., Mercado N., Poldermans D., et al. Acute myocardial infarction. Lancet 361 9360 (2003) 847-858
23. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343 21 (2000) 1520-1528
24. Bonetti P.O., Lerman L.O., and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23 2 (2003) 168-175
25. Bonfiglio T., and Atwater E.C. Heart disease in patients with seropositive rheumatoid arthritis; a controlled autopsy study and review. Arch. Int. Med. 124 6 (1969) 714-719
26. Booth G.L., and Wang X.L. Preventative health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. Can. Med. Assoc. J. 163 1 (2000) 21-29
27. Breen J. Imaging of the pericardium. J. Thora. Imag. 16 (2001) 47-54
28. Callahan L.F., Cordray D.S., Wells G., et al. Formal education and five-year mortality in rheumatoid arthritis: mediation by helplessness scale score. Arthritis Care Res. 9 6 (1996) 463-472
29. Carmona L., Balsa A., Gonzalez-Alvaro I., et al. Decreased prevalence of diabetes in rheumatoid arthritis patients compared to the general population after standardisation by age. Rheumatology 41 (2002) S71
30. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345 25 (2001) 1809-1817 Study identified the potential for ibuprofen to reduce the anti-platelet effects of aspirin
31. Cathcart E.S., and Spodick D. Rheumatoid heart disease. N. Engl. J. Med. 266 (1962) 959-964
32. Chand E.M., Freant L.J., and Rubin J.W. Aortic valve rheumatoid nodules producing clinical aortic regurgitation and a review of the literature. Cardiovasc. Pathol. 8 6 (1999) 333-338
33. Chapman M.J., Guerin M., and Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur. Heart J. 19 (1998) Suppl-30
34. Charcot J.M. Clinical Lectures on Senile and Chronic Disease (1881), New Syddenham Society, London p. 95
35. Chehata J.C., Hassell A.B., Clarke S.A., et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 40 4 (2001) 447-452
36. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 9313 (2002) 1173-1177
37. Cisternas M., Gutierrez M.A., Klaassen, et al. Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J. Rheumatol. 29 8 (2002) 1619-1622
38. Coste J., and Jougla E. Mortality from rheumatoid arthritis in France, 1970-1990. Int. J. Epidemiol. 23 3 (1994) 545-552
39. Criswell L.A., Merlino L.A., Cerhan J., et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am. J. Med. 112 6 (2002) 465-471
40. Curtis B.M., and O'Keefe Jr. J.H. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clinic Proc. 77 1 (2002) 45-54
41. Dai L., Lamb D.J., Leake D.S., et al. Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients. Free Radical Res. 32 6 (2000) 479-486
42. Danesh J., Collins R., Appleby P., and Peto R. Association of C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279 18 (1998) 1477-1482
43. Dasgupta A., Banerjee S.K., and Datta P. False-positive troponin I in the MEIA due to the presence of rheumatoid factors in serum-elimination of this interference by using a polyclonal antisera against rheumatoid factors. Am. J. Clin. Pathol. 112 6 (1999) 753-756
44. Dawber T. The Framingham Study: The Epidemiology of Atherosclerotic Disease (1980), Harvard University Press, Cambridge, MA
45. Dawson J.K., Goodson N.G., Graham D., et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology 39 12 (2000) 1320-1325
46. del Rincon I.D., Williams K., Stern M.P., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44 12 (2001) 2737-2745 Increased CVD events were identified in RA patients compared to control population. The prevalence of traditional CVD risk factors did not explain this excess
47. Dessein P.H., Joffe B.I., Stanwix A., et al. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J. Rheumatol. 29 3 (2002) 462-466
48. Devlin J., Gough A., Huissoon A., et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J. Rheumatol. 24 1 (1997) 9-13
49. Doran M.F., Pond G.R., Crowson C.S., et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 46 3 (2002) 625-631 The incidence of RA reduced during this study. But mortality rates remained increased in RA patients compared to the general population
50. Erb N., Banks M., Rowe I.F.D., et al. Classical risk factors for ischaemic heart disease (IHD) and their modification in patients with rheumatoid arthritis (RA). Arthritis Rheum. 44 9 (2001) S59
51. Ernst E., and Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis. Ann. Intern. Med. 118 (1993) 956-963
52. Fernandez-Muixi J., Vidal F., Bardaji A., et al. Recurrent pericarditis and cardiac tamponade in rheumatoid arthritis: effectiveness of colchicine. Br. J. Rheumatol. 33 6 (1994) 596-597
53. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345 6 (2001) 433-442
54. Folsom A.R., Aleksic N., Catellier D., et al. C-Reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am. Heart J. 144 2 (2002) 233-238
55. Frishman W.H. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am. J. Cardiol. 89 6 (2002) 18-25
56. Gabriel S., Crowson C., and O'Fallon M. Comorbidity in arthritis. J. Rheumatol. 26 (1999) 2475-2479
57. Gabriel S.E., Crowson C.S., and O'Fallon W.M. Mortality in rheumatoid arthritis: have we made an impact in 4 decades?. J. Rheumatol. 26 12 (1999) 2529-2533
58. Gabriel S.E., Crowson C.S., Kremers H., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 48 (2003) 54-58
59. Garnero A., Fasciolo D., Accardo S., and Seriolo B. Cardiac risk factors in patients with rheumatoid arthritis. Ann. Rheum. Dis. Suppl. (1999) 69-70 abstract
60. Gaylord G.M. Computed tomographic and magnetic resonance coronary angiography: are you ready?. Radiol. Mgmt 24 4 (2002) 16-20
61. Goldeli O., Dursun E., and Komsuoglu B. Dispersion of ventricular repolarization: a new marker of ventricular arrhythmias in patients with rheumatoid arthritis. J. Rheumatol. 25 3 (1998) 447-450
62. Goodson N.J., Pattison D.J., Lunt M., et al. Cardiovascular risk factors are not increased prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 41 (2002) 9 no. abstracts supplement
63. Goodson N.J., Wiles N.J., Lunt M., et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46 8 (2002) 2010-2019
64. Gordon D.A., Stein J.L., and Broder I. The extra-articular features of rheumatoid arthritis: a systematic analysis of 127 cases. Am. J. Med. 54 (1973) 445-452
65. Gordon M.M., Thomson E.A., Madhok R., et al. Can intervention modify adverse lifestyle variables in a rheumatoid population? Results of a pilot study. Ann. Rheum. Dis. 61 1 (2002) 66-69
66. Goyle K.K., and Walling A.D. Diagnosing pericarditis. Am. Family Phys. 66 9 (2002) 1695-1702
67. Grundy S., Pasternak R., Greenland P., et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American college of cardiology. Circulation 100 (1999) 1481-1492
68. Guedes C., Bianchi-Fior P., Cormier B., et al. Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum. 45 2 (2001) 129-135
69. Haagsma C.J., Blom H.J., van-Riel P.L.C.M., et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann. Rheum. Dis. 58 (1999) 79-84
70. Hara K.S., Ballard D.J., Ilstrup D., et al. Rheumatoid pericarditis: clinical features and survival. Medicine 69 2 (1990) 81-91 Follow up study of 41 RA patients presenting with pericarditis. Describes clinical presentation and outcomes
71. Heliövaara M., Aho K., and Aromaa A. Smoking as a risk of rheumatoid arthritis. J. Rheumatol. 20 (1993) 1830-1835
72. Heliövaara M., Aho K., Knekt P., Reunanen A., and Aromaa A. Serum cholesterol and risk of rheumatoid arthritis in a cohort of 52800 men and women. Br. J. Rheumatol. 35 (1996) 255-257
73. Heller R.F., Chinn S., Tunstall-Pedoe H., et al. How well can we predict coronary heart disease?. BMJ 288 (1984) 410-411
74. Hennekens C.H., and Buring J.E. Epidemiology in Medicine. first ed (1987), Little, Brown and Company, Boston/Toronto
75. Hilbrands L.B., Demacker P.N., Hoitsma A., et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J. Am. Soc. Nephrol. 5 12 (1995) 2073-2081
76. Hurlimann D., Forster A., Noll G., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 17 (2002) 2184-2187
77. Hurt-Camejo E., Paredes S., Masana L., et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 44 12 (2001) 2761-2767
78. Hutchinson D., Shepstone L., Moots R., et al. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann. Rheum. Dis. 60 3 (2001) 223-227 Increasing amount of cigarette smoking is associated with increased odds of having RA
79. Ichikawa Y., Yamada C., Horiki T., et al. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 16 5 (1998) 533-540
80. Jacobsson L.T.H., Knowler W.C., Pillemer S., et al. Rheumatoid-arthritis and mortality-a longitudinal-study in Pima-indians. Arthritis Rheum. 36 8 (1993) 1045-1053
81. Jansen L.M., van der Horst-Bruinsma I.E., Van schaardenburg D., et al. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 60 10 (2001) 924-927
82. Kamper E.F., Kopeikina L.T., Trontzas P., et al. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis. J. Rheumatol. 27 11 (2000) 2545-2550
83. Kaplan D., and Feldman J. A Preliminary study of excess cardiovascular disease in the mothers of patients with RA. Am. J. Epidemiol. 133 (1991) 715-720
84. Kaplan M.J., and Clune W.J. New evidence for vascular disease in patients with early rheumatoid disease. Lancet 316 (2003) 1068-1069
85. Karlson E.W., Lee I.M., Cook N., et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum. 42 5 (1999) 910-917
86. Kent S.M., Flaherty P.J., Coyle L.C., et al. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am. Heart J. 145 2 (2003) e8
87. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur. Heart J. 19 (1998) Suppl. 43
88. Koenig W., Sund M., Frolich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augburg study 1984 to 1992. Circulation 99 2 (1999) 237-242
89. Kopeikina L.T., Kamper E.F., Koutsoukos V., et al. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin. Rheumatol. 16 3 (1997) 254-260
90. Koukkunen H., Penttila K., Kemppainen A., et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann. Med. 33 1 (2001) 37-47
91. Krause D., and Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 43 (2000) 14-21
92. Kroot E.J.A., van Leeuwen M.A., van Rijswijk M.H., et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann. Rheum. Dis. 59 12 (2000) 954-958 Study of survival in RA patients with onset of disease in 1980s-1990s. Suggests an improved mortality outcome in RA over recent years
93. Kroot E.J.A., van Gestel A.M., Swinkels H.L., et al. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J. Rheumatol. 28 7 (2001) 1511-1517
94. Kullo I., Gau G., and Tajik A. Novel risk factors for atherosclerosis. Mayo Clinic Proc. 75 (2000) 369-380
95. Kumeda Y., Inaba M., Goto H., et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 46 6 (2002) 1489-1497
96. Kvalvik A.G., Jones M.A., and Symmons D.P.M. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand. J. Rheumatol. 29 1 (2000) 29-37
97. Lakatos J., and Harsagyi A. Serum total, HDL, LDL cholesterol and triglyceride levels in patients with rheumatoid arthritis. Clin. Biochem. 21 (1988) 93-96
98. Landewe R.B., van den Borne B.E., Breedveld F.C., et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355 9215 (2000) 1616-1617
99. Lazarevic B., Vitic J., Mladenovic V., et al. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin. Arthritis Rheum. 22 3 (1992) 172-180
100. Leden I., Eriksson A., Lilja B., et al. Autonomic nerve function in rheumatoid arthritis of varying severity. Scand. J. Rheumatol. 12 2 (1983) 166-170
101. Lee A.J., Fowkes F.G., Lowe G.D., et al. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb. Haemost. 74 3 (1995) 828-832
102. Lee Y.H., Choi S.J., Ji J.D., et al. Lipoprotein (a) and lipids in relation to inflammation in rheumatoid arthritis. Clin. Rheumatol. 19 4 (2000) 324-325
103. Levine A.J., Dimitri W.R., and Bonser R.S. Aortic regurgitation in rheumatoid arthritis necessitating aortic valve replacement. Eur. J. Cardio-Thorac. Surg. 15 2 (1999) 213-214
104. Liebowitz W.B. The heart in rheumatoid arthritis: a clinical and pathological study of 62 cases. Ann. Int. Med. 58 (1963) 102-110
105. Lindqvist E., and Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann. Rheum. Dis. 58 (1999) 11-14
106. Listing J., Rau R., Muller B., et al. HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group. J. Rheumatol. 27 9 (2000) 2100-2109
107. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., and Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331 7 (1994) 417-424
108. Lochen M.L. The Tromso study: the prevalence of exercise-induced silent myocardial ischaemia and relation to risk factors for coronary heart disease in an apparently healthy population. Eur. Heart J. 13 6 (1992) 728-731
109. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler. Thromb. Vasc. Biol. 21 9 (2001) 1451-1457
110. Magadle R., Weiner P., Beckerman M., et al. C-reactive protein as a marker for active coronary artery disease in patients with chest pain in the emergency room. Clin. Cardiol. 25 10 (2002) 456-460
111. Magliano D.J., Liew D., Ashton E.L., et al. Novel biomedical risk markers for cardiovascular disease. J. Cardiovasc. Risk 10 1 (2003) 41-55
112. Maione S., Valentini G., Giunta A., et al. Cardiac involvement in rheumatoid arthritis: an echocardiographic study. Cardiology 83 4 (1993) 234-239
113. Manji H., and Raven P. Calcific constrictive pericarditis due to rheumatoid arthritis. Postgrad. Med. J. 66 771 (1990) 57-58
114. Masdottir B., Jonsson T., Manfredsdottir V., et al. Smoking, rheumatoid factor iso types and severity of rheumatoid arthritis. Rheumatology 39 11 (2000) 1202-1205
115. May O., Arildsen H., Damsgaard E.M., et al. Prevalence and prediction of silent ischaemia in diabetes mellitus: a population-based study. Cardiovasc. Res. 34 1 (1997) 241-247
116. McEntegart A., Capell H.A., Duncan M.R., et al. Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann. Rheum. Dis. 56 (1997) 410-413
117. McEntegart A., Capell H.A., Creran D., et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40 6 (2001) 640-644
118. McEntegart A., Capell H.A., and Madhok R. Predicting coronary risk in rheumatoid arthritis. Arthritis Rheum. 44 9 (2001) s53
119. Mikuls T.R., and Moreland L.W. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Safety 26 1 (2003) 23-32
120. Mikuls T.R., Saag K.G., Criswell L.A., et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann. Rheum. Dis. 61 11 (2002) 994-999
121. Mody G.M., Stevens J.E., and Meyers O.L. The heart in rheumatoid arthritis-a clinical and echocardiographic study. QJM 65 247 (1987) 921-928
122. Morgan S.L., Baggott J.E., Lee J.Y., et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease. J. Rheumatol. 25 (1998) 441-446
123. Mounet F., Soula P., Concina P., et al. Specific valvular heart disease of rheumatoid arthritis: two case reports. Arch. Mal. Coeur Vaiss. 90 7 (1997) 987-989
124. Munro R., Morrison E., McDonald A.G., et al. Effect of disease modifying agents on the lipid profiles of patients with rhuematoid arthritis. Ann. Rheum. Dis. 56 (1997) 374-377 Study that revealed a favourable effect of hydroxychloroquine on lipid profiles in RA patients
125. Myllykangas-Luosujärvi R., Aho K., Kautianen H., et al. Cardiovascular mortality in women with rheumatoid arthritis. J. Rheumatol. 22 (1995) 1065-1067
126. Nalbantgil I., Onder R., Nalbantgil S., et al. The prevalence of silent myocardial ischaemia in patients with white-coat hypertension. J. Hum. Hypertens. 12 5 (1998) 337-341
127. Nomeir A.M., Turner R.A., and Watts L.E. Cardiac involvement in rheumatoid arthritis. Followup study. Arthritis Rheum. 22 6 (1979) 561-564
128. Nosal' R., Jancinova V., and Danihelova E. Chloroquine: a multipotent inhibitor of human platelets in vitro. Thrombosis Res. 98 5 (2000) 411-421
129. Nurmohamed M.T., van Halm V.P., and Dijkmans B.A. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 62 11 (2002) 1599-1609 Review of cardiovascular effects of NSAIDs and DMARDs
130. Okada Y., Nakanishi I., Kajikawa K., et al. An autopsy case of rheumatoid arthritis with an involvement of the cardiac conduction system. Jpn. Circ. J. 47 6 (1983) 671-676
131. Park Y.B., Lee S.K., Lee W.K., et al. Lipid profiles in untreated patients with rheumatoid arthritis. J. Rheumatol. 26 8 (1999) 1701-1704
132. Park Y.B., Ahn C.W., Choi H.K., et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 46 7 (2002) 1714-1719
133. Park Y.B., Choi H.K., Kim M.Y., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am. J. Med. 113 3 (2002) 188-193
134. Payami H., Khan M.H., Grennan D.M., et al. Analysis of genetic interrelationship among HLA-associated diseases. Am. J. Hum. Genet. 41 3 (1987) 331-349
135. Peltomaa R., Paimela L., Kautiainen H., et al. Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann. Rheum. Dis. 61 10 (2002) 889-894
136. Pincus T., and Callahan L.F. What is the natural history of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 19 (1993) 123-146
137. Plant M.J., Williams A.L., O'Sullivan M.M., et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum. 43 7 (2000) 1473-1477
138. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease-prospective analysis from the Women's Health Initiative observational study. JAMA 288 8 (2002) 980-987
139. Rantapää-Dahlqvist S., Wållberg-Jonsson S., and Dahlèn G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann. Rheum. Dis. 50 (1991) 366-368
140. Raza K., Thambyrajah J., Townend J.N., et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease?. Circulation 102 13 (2000) 1470-1472
141. Reckner O.A., Skogh T., and Wingren G. Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis. Ann. Rheum. Dis. 60 10 (2001) 934-939
142. Reilly P., Cosh J.A., and Maddison P.J. Mortality and survival in rheumatoid arthritis: a 25 year study of 100 patients. Ann. Rheum. Dis. 49 (1990) 363-369
143. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 3 (2003) 363-369
144. Ridker P.M. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin. Cardiol. 26 4 Suppl. 3 (2003) III39-III44
145. Ridker P.M., Cushman M., Stampher M.J., et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 (1997) 973-979
146. Ridker P.M., Manson J.E., Buring J.E., et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281 19 (1999) 1817-1821
147. Ridker P.M., Hennikens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
148. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347 20 (2002) 1557-1565 C-reactive protein identified as a stronger predictor of CVD events than LDL-cholesterol levels in apparently healthy women
149. Riise T., Jacobsen B.K., Gran J.T., et al. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin. Rheumatol. 20 2 (2001) 123-127
150. Rodriguez G., Sulli A., and Cutolo M. Carotid atherosclerosis in patients with rheumatoid arthritis: a preliminary case-control study. Ann. NY Acad. Sci. 966 (2002) 478-482
151. Roos J.M., Aubry M.C., and Edwards W.D. Chloroquine cardiotoxicity clinicopathologic features in three patients and comparison with three patients with Fabry disease. Cardiovasc. Pathol. 11 5 (2002) 277-283
152. Rose G.A. The diagnosis of ischaemic heart pain and intermittent claudication in field studies. Bull. WHO 27 (1967) 645-658
153. Rosenson R.S., and Koenig W. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Curr. Opin. Cardiol. 17 4 (2002) 325-331
154. Ross R. Mechanisms of disease: atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 2 (1999) 115-126
155. Roubenoff R., Dellaripa P., Nadeau M., et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 40 4 (1997) 718-722
156. Saag K.G., Cerhan J.R., and Kolluri S. Cigarette smoking and rheumatoid disease severity. Ann. Rheum. Dis. 56 (1997) 463-470
157. Salonen R., Nyyssonen K., and Porkkala E. Kuopio atherosclerosis prevention study (KAPS). A population-based primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92 (1995) 1758-1764
158. Scheuner M.T. Genetic predisposition to coronary artery disease. Curr. Opin. Cardiol. 16 4 (2001) 251-260
159. Sigal L.H., and Friedman H.D. Rheumatoid pancarditis in a patient with well controlled rheumatoid arthritis. J. Rheumatol. 16 3 (1989) 368-373
160. Silman A.J. Trends in the incidence and severity of rheumatoid arthritis. J. Rheumatol. Suppl. 32 (1992) 71-73
161. Silman A.J. The changing face of rheumatoid arthritis: why the decline in incidence?. Arthritis Rheum. 46 3 (2002) 579-581
162. Silman A.J., Newman J., and MacGregor A.J. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 39 5 (1996) 732-735
163. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 10 (2000) 1247-1255
164. Sinha A.K., Eigenbrodt M., and Mehta J.L. Does carotid intima media thickness indicate coronary atherosclerosis?. Curr. Opin. Cardiol. 17 5 (2002) 526-530
165. Situnayake R.D., and Kitas G. Dyslipidaemia and rheumatoid arthritis. Ann. Rheum. Dis. 56 (1997) 341-342 Reviews the literature regarding lipid abnormalities associated with RA
166. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand. J. Rheumatol. 30 5 (2001) 305-307
167. Sokka T., Mottonen T., and Hannonen P. Mortality in early sawtooth treated rheumatoid arthritis patients during the first 8-14 years. Scand. J. Rheumatol. 28 (1999) 282-287
168. Solomon D.H., and Avorn J. Pharmacoepidemiology and rheumatic diseases: 2001-2002. Curr. Opin. Rheumatol. 15 2 (2003) 122-126
169. Solomon D.H.M., Karlson E.W.M., Rimm E.B.S., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 9 (2003) 1303-1307 Study observed a threefold increase in rate of myocardial infarction in women diagnosed as having RA
170. Spector T.D., and Silman A.J. Parental mortality and rheumatoid-arthritis. J. Rheumatol. 15 1 (1988) 150
171. Stein M., Bell M.J., and Ang L.C. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 27 12 (2000) 2927-2931
172. Svenson K.L., Lithell H., Hallgren R., et al. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch. Int. Med. 147 11 (1987) 1917-1920
173. Svenson K.L., Pollare T., Lithell H., et al. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 37 2 (1988) 125-130
174. Symmons D.P.M. Epidemiolgy of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract. Res. Clin. Rheumatol. 16 5 (2002) 707-722
175. Symmons D.P.M., Bankhead C.R., Harrison B.J., et al. Blood transfusion, smoking and obesity as risk factors for development of rheumatoid arthritis: results from a primary care based incident case-control study in Norfolk, England. Arthritis Rheum. 40 (1997) 1955-1961
176. Symmons D.P.M., Jones M.A., Scott D.L., et al. Longterm mortality outcomes in patients with rheumatoid arthritis: early presenters continue to do well. J. Rheumatol. 25 6 (1998) 1072-1077
177. Taler S.J., Textor S.C., Canzanello V.J., et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Safety 20 5 (1999) 437-449
178. Tanimoto N., Kumon Y., Suehiro T., et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72 25 (2003) 2877-2885
179. Thould A.K. Constrictive pericarditis in rheumatoid arthritis. Ann. Rheum. Dis. 45 2 (1986) 89-94
180. Tlustochowicz W. Echocardiographic evaluation of cardiac structures in patients with rheumatoid arthritis. Polskie Archiwum Medycyny Wewnetrznej 97 4 (1997) 352-358
181. Tlustochowicz W., Piotrowicz R., Cwetsch A., et al. 24-h ECG monitoring in patients with rheumatoid arthritis. Eur. Heart J. 16 6 (1995) 848-851
182. Toumanidis S.T., Papamichael C.M., Antoniades L.G., et al. Cardiac involvement in collagen diseases. Eur. Heart J. 16 2 (1995) 257-262
183. Toussirot E., Serratrice G., and Valentin P. Autonomic nervous-system involvement in rheumatoid-arthritis-50 cases. J. Rheumatol. 20 9 (1993) 1508
184. Tracy R.P. Inflammation markers and coronary heart disease. Curr. Opin. Lipidol. 10 5 (1999) 435-441
185. Turesson C., Jacobsson L., and Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology 38 (1999) 668-674
186. Turesson C., Jacobsson L., Bergstrom U., et al. Predictors of extra-articular manifestations in rheumatoid arthritis. Scand. J. Rheumatol. 29 6 (2000) 358-364
187. Van Doornum S., McColl G., Jenkins A., et al. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum. 48 1 (2003) 72-80
188. van Ede A.E., Laan R.F., Blom H.J., et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 41 6 (2002) 658-665
189. Verma S., Raj S.R., Shewchuk L., et al. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 104 24 (2001) 2879-2882
190. Wallace D.J., Metzger A.L., Stetcher V.J., et al. Cholesterol lowering effects of Hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids. Am. J. Med. 89 (1990) 322-326
191. Wållberg-Jonsson S., Öhman M.L., and Rantapää-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J. Rheumatol. 24 (1997) 445-451 Study identified increased IHD events and CVD mortality in established RA patients
192. Wållberg-Jonsson S., Johansson H., Ohman M.L., et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J. Rheumatol. 26 12 (1999) 2562-2571
193. Wållberg-Jonsson S., Cederfelt M., and Rantapää-Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow-up study. J. Rheumatol. 27 1 (2000) 71
194. Wållberg-Jonsson S., Backman C., Johnson O., et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J. Rheumatol. 28 (2001) 2597-2602
195. Ward M.M. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs?. Arthritis Rheum. 44 6 (2001) 1467-1469
196. Ward R.P., and Lang R.M. Myocardial contrast echocardiography in acute coronary syndromes. Curr. Opin. Cardiol. 17 5 (2002) 455-463
197. Watson D.J., Rhodes T., Cai B., et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Int. Med. 162 10 (2002) 1105-1110
198. Webber M.D., Selsky E.J., and Roper P.A. Identification of a mobile intracardiac rheumatoid nodule mimicking an atrial myxoma. J. Am. Soc. Echocardiogr. 8 6 (1995) 961-964
199. Wislowska M., Sypula S., and Kowalick I. Echocardiographic findings, 24 hour electrocardiographic holter monitoring in patients with rheumatoid arthritis according to Steinbroker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin. Rheumatol. 17 (1998) 369-377
200. Wislowska M., Sypula S., and Kowalik I. Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol. Int. 18 5-6 (1999) 163
201. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J. Rheumatol. 27 (2000) 630-637
202. Wolfe F., Mitchell D.M., and Sibley J.T. The mortality of rheumatoid arthritis. Arthritis Rheum. 37 (1994) 481-494 Large population and clinic based studies of mortality outcomes in RA patients
203. Wolfe F., Freundlich B., and Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J. Rheumatol. 30 1 (2003) 36-40
204. Wood D., Durrington P.N., Poulter N., et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 80 2 (1998) S1-S29
205. Yasojima K., Schwab C., McGeer E.G., et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol. 158 3 (2001) 1039-1051